410 related articles for article (PubMed ID: 21389735)
1. Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients?
Onuigbo MA
Nephron Clin Pract; 2011; 118(4):c407-19. PubMed ID: 21389735
[TBL] [Abstract][Full Text] [Related]
2. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
Onuigbo MA; Onuigbo NT
QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
[TBL] [Abstract][Full Text] [Related]
3. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
4. Renal failure and concurrent RAAS blockade in older CKD patients with renal artery stenosis: an extended Mayo Clinic prospective 63-month experience.
Onuigbo MA; Onuigbo NT
Ren Fail; 2008; 30(4):363-71. PubMed ID: 18569908
[TBL] [Abstract][Full Text] [Related]
5. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice.
Onuigbo MA
Hemodial Int; 2009 Oct; 13 Suppl 1():S24-9. PubMed ID: 19775421
[TBL] [Abstract][Full Text] [Related]
6. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
8. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
[TBL] [Abstract][Full Text] [Related]
9. Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution.
Onuigbo MA
Nephron Clin Pract; 2009; 113(2):c63-9, discussion c70. PubMed ID: 19602900
[TBL] [Abstract][Full Text] [Related]
10. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
Toto R; Palmer BF
Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
[TBL] [Abstract][Full Text] [Related]
11. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
12. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
13. Angioedema related to Angiotensin inhibitors.
Knecht SE; Dunn SP; Macaulay TE
J Pharm Pract; 2014 Oct; 27(5):461-5. PubMed ID: 25124378
[TBL] [Abstract][Full Text] [Related]
14. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
[TBL] [Abstract][Full Text] [Related]
15. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H
Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
[TBL] [Abstract][Full Text] [Related]
16. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
[TBL] [Abstract][Full Text] [Related]
17. [The clinical usefulness of RAAS inhibitors in hypertensive patients].
Yamaguchi K; Sata M
Nihon Rinsho; 2012 Sep; 70(9):1571-6. PubMed ID: 23012805
[TBL] [Abstract][Full Text] [Related]
18. Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention.
Vijayaraghavan K; Deedwania P
Cardiol Clin; 2011 Feb; 29(1):137-56. PubMed ID: 21257105
[TBL] [Abstract][Full Text] [Related]
19. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
Heerspink HJ
Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
